Axsome Therapeutics (AXSM) Payables: 2022-2025
Historic Payables for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $225.6 million.
- Axsome Therapeutics' Payables rose 84.68% to $225.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $693.7 million, marking a year-over-year increase of 68.31%. This contributed to the annual value of $148.0 million for FY2024, which is 63.52% up from last year.
- Latest data reveals that Axsome Therapeutics reported Payables of $225.6 million as of Q3 2025, which was up 32.02% from $170.9 million recorded in Q2 2025.
- Axsome Therapeutics' 5-year Payables high stood at $225.6 million for Q3 2025, and its period low was $12.6 million during Q1 2022.
- Over the past 3 years, Axsome Therapeutics' median Payables value was $116.8 million (recorded in 2024), while the average stood at $118.9 million.
- Data for Axsome Therapeutics' Payables shows a peak YoY surged of 366.64% (in 2023) over the last 5 years.
- Quarterly analysis of 4 years shows Axsome Therapeutics' Payables stood at $51.6 million in 2022, then skyrocketed by 75.28% to $90.5 million in 2023, then soared by 63.52% to $148.0 million in 2024, then skyrocketed by 84.68% to $225.6 million in 2025.
- Its Payables was $225.6 million in Q3 2025, compared to $170.9 million in Q2 2025 and $149.2 million in Q1 2025.